Condition
Endometrial Carcinoma (EC)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownStudy of GV20-0251 in Participants With Solid Tumor MalignanciesNCT07070518 · 2025-07-11
RECRUITINGA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesNCT05669430 · 2023-03-23
RECRUITINGA Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K MutationsNCT07038369 · 2025-07-29
ACTIVE_NOT_RECRUITINGCommon interventions
Leading sponsors
Trial status mix
RECRUITING2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE13
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.